Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Promotion of breast cancer metastasis by tumor-induced myeloid-derived suppressor cells

EF 2016-17

Résumé
The vast majority of cancer-related deaths are due to metastasis. During this process, cancer cells detach from the primary tumor site and travel to organs throughout the body, such as the lungs and liver. Various tumor-secreted factors can cause the accumulation of myeloid-derived suppressor cells (MDSCs) in tissues of mice bearing metastatic mammary carcinomas. These MDSCs actively suppress anti-tumor T cell mediated immune responses, as well as promote the development and growth of metastatic tumor foci. Though we have found that MDSC content is reduced in the lungs following surgical resection of the primary tumor, the frequency of MDSCs still remains 5-10 fold higher relative to naïve mice. We hypothesize that the population of MDSCs that persists in the lungs following surgical resection is a unique population of MDSCs that promote metastatic tumor growth and actively suppress immune cells located in metastatic niches. We will isolate bulk MDSCs and MDSCs that persist in the lungs following tumor resection and 1) perform a proteomics screen to determine differences in cell surface marker expression, 2) compare the ability of these two MDSC populations to suppress T cell activation, and 3) compare drug sensitivities of persistent MDSCs and bulk MDSCs. Current options for treating metastatic cancer are very limited. We postulate that the MDSCs that persist after tumor resection contribute to a lung environment which supports subsequent metastatic tumor growth, and previous data from our lab supports targeting immunosuppressive myeloid cells to treat metastatic breast cancer. Our work will therefore aid in developing therapies to target MDSCs to treat patients with metastatic breast cancer.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
367082
Name
Cederberg Rachel
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Promotion of breast cancer metastasis by tumor-induced myeloid-derived suppressor cells
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Breast Cancer; Cytotoxic Lymphocytes; Immunosuppression; Metastasis; Metastatic Niches; Myeloid-Derived Suppressor Cells; Proteomics; Tumor Hypoxia; Tumor Immune Evasion; Tumor-Secreted Factors
Abstract
The vast majority of cancer-related deaths are due to metastasis. During this process, cancer cells detach from the primary tumor site and travel to organs throughout the body, such as the lungs and liver. Various tumor-secreted factors can cause the accumulation of myeloid-derived suppressor cells (MDSCs) in tissues of mice bearing metastatic mammary carcinomas. These MDSCs actively suppress anti-tumor T cell mediated immune responses, as well as promote the development and growth of metastatic tumor foci. Though we have found that MDSC content is reduced in the lungs following surgical resection of the primary tumor, the frequency of MDSCs still remains 5-10 fold higher relative to naïve mice. We hypothesize that the population of MDSCs that persists in the lungs following surgical resection is a unique population of MDSCs that promote metastatic tumor growth and actively suppress immune cells located in metastatic niches. We will isolate bulk MDSCs and MDSCs that persist in the lungs following tumor resection and 1) perform a proteomics screen to determine differences in cell surface marker expression, 2) compare the ability of these two MDSC populations to suppress T cell activation, and 3) compare drug sensitivities of persistent MDSCs and bulk MDSCs. Current options for treating metastatic cancer are very limited. We postulate that the MDSCs that persist after tumor resection contribute to a lung environment which supports subsequent metastatic tumor growth, and previous data from our lab supports targeting immunosuppressive myeloid cells to treat metastatic breast cancer. Our work will therefore aid in developing therapies to target MDSCs to treat patients with metastatic breast cancer.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Cederberg, Rachel
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~